AsiaNet Daily Summary - Press Releases for Wednesday, Sept 10, 2008

SYDNEY--10 Sep--AsiaNet/InfoQuest


FENOFIBRATE DIABETES...

ROME - Exciting New Data From the FIELD Study Show

Additional Microvascular-Associated Benefits of Fenofibrate.
The First Time in a Large-Scale Prospective Study That any
Lipid-Modifying Therapy Has Been Shown to Significantly Reduce
the Risk of Lower-Limb Amputation in Patients With Type 2
Diabetes. http://www.prnewswire.co.uk/cgi/news
release?id=236272

VIVAGEL CONDOM...

MELBOURNE - Starpharma Holdings Limited (ASX:SPL,

OTCQX:SPHRY) today announced that a full licence agreement has
been signed with SSL International plc (LSE:SSL) in relation to
the VivaGel coated condom. SSL manufactures and sells Durex
condoms, the market-leading condom brand worldwide.
www.starpharma.com

CHINA CABLECOM Q2...

SHANGHAI - China Cablecom Holdings, Ltd. ("China Cablecom")

(Nasdaq: CABL; CABLW; CABLU), a joint-venture provider of cable
television services in the People's Republic of China (PRC),
announced today its unaudited financial results for the second
quarter ended June 30, 2008.
http://www.chinacablecom.net

O.BERK INTRODUCTIONS...

UNION, N.J.- O.BERK Company along with the Cosmetic

Packaging Group will be promoting several new and exciting
products and services at HBA Global Expo in New York in
September. The Cosmetic Packaging Group will not only be
displaying its new collection of glass bottles and jars, but
will be releasing its updated "Pocket Container Sourcebook."
This booklet contains the Group's available line of glass,
plastic and metal bottles, jars, cans, and closures, and
complements both its printed and online catalogs.
http://www.OBERK.com

ATMEL INTRODUCTION...

HEILBRONN - Atmel(R) (Nasdaq: ATML) announced today a

significant enhancement to the ATA2270-EK1 125-kHz RFID demo
kit. This kit, which enables the evaluation and prototyping of
Atmel's wide portfolio of LF IDIC(R)s, has been upgraded to
include a PC-based GUI application to be connected directly to
the kit's hardware. This new user interface provides an
optimized platform for the evaluation and customization of
Atmel's RFID solutions used in access control, industrial
automation, loyalty cards, anti-counterfeiting, and animal
identification. Configuration of Atmel tags in all available
modes and the selection of the most suitable RFID solution
without advanced knowledge of RF engineering have been made
even easier.
http://www.atmel.com

FANNIE MAE...

WASHINGTON, D.C.: Fannie Mae will redeem the principal

amount of MTN securities issues amounting to a total of US$75
million on 19 September, 2008 at a redemption price equal to
100 per cent of the principal amount redeemed plus accrued
interest. http://www.fanniemae.com

FANNIE MAE...

WASHINGTON, D.C.: Fannie Mae will redeem the principal

amount of MTNR securities issues amounting to a total of US$25
million on 19 September, 2008 at a redemption price equal to
100 per cent of the principal amount redeemed plus accrued
interest. http://www.fanniemae.com

ANADIGICS SHOWCASE...

WARREN, N.J. - ANADIGICS, Inc. (Nasdaq: ANAD) today

announced that it will be attending three major industry events
in China: the Global WiMAX Summit in Beijing from September
18th to 19th; PT/ExpoComm in Beijing from October 21st to 25th;
and the Mobile Asia Congress in Macau from November 18th to
20th.
http://www.anadigics.com

VALE NEGOTIATIONS...

RIO DE JANEIRO - Companhia Vale do Rio Doce (NYSE: RIO)

(Vale), in compliance with a determination of Brazil's Comissao
de Valores Mobiliarios (CVM), informs that it is negotiating
with Asian clients the convergence of reference prices for iron
ore to the same level of those charged to European clients.
Currently, reference prices for Asian clients are 11.0% to
11.5% lower than prices for Europe, depending on the type of
iron ore.
http://www.vale.com

FANNIE MAE ANNOUNCEMENT...

WASHINGTON, Sept. 10 /PRNewswire-AsiaNet/ --

The following is being issued by Fannie Mae (NYSE: FNM):
2-Year Pricing Date September 10, 2008
Settlement Date September 12, 2008
Maturity Date October 12, 2010
Issue Size TBD
Coupon TBD
Payment Dates Each October 12th and April 12th, beginning
October 12, 2008
CUSIP 31398ATZ5
Listing Application will be made to list the securities on
the EuroMTF market of the Luxembourg Stock Exchange
Barclays Capital Inc., Citigroup Global Markets Inc., and
J.P. Morgan Securities Inc. are the joint lead managers. The
co-managers include Deutsche Bank Securities Inc., Goldman
Sachs & Co., and UBS Securities LLC.
http://www.fanniemae.com

PLATTS SURVEY...

LONDON - The 13 members of the Organization of the Petroleum

Exporting Countries (OPEC) pumped an average 32.81 million
barrels per day (b/d) of crude oil in August, a Platts survey
of OPEC and oil industry officials showed September 9. This is
40,000 b/d higher than the July production of 32.77 million b
d.
http://www.mcgraw-hill.com.

JETSTAR PACIFIC...

HO CHI MINH CITY - Special launch fares just $2USD# one way

Every Day one way fares from $12USD# one way Jetstar Pacific,
Vietnams low fares airline, will expand into international
markets for the first time under the Jetstar brand offering
daily direct services from Ho Chi Minh City to Bangkok*
(Thailand) and Siem Reap* (Cambodia).

RTS REALTIME...

CHICAGO and FRANKFURT - What:A seminar on algorithmic

trading trends, news and opportunities [immediately prior to
the FIA Asia Derivatives Conference] When: September 17, 2008,
9:30 a.m. Tokyo time. Where: FIA Asia Derivatives Conference
Sakura-A Room Tokyo Westin 1-4-1 Mita, Meguro-ku Tokyo,
Japan.
http://www.rtsgroup.net

SOURCE: AsiaNet

AsiaNet is a consortium of leading news agencies

distributing unedited, translated news releases for worldwide
clients. Visit www.asianetnews.net for full-text versions.

ข่าวType 2 Diabetes+news releaseวันนี้

AsiaNet Daily Summary - Press Releases for Wednesday, Sept 10, 2008

FENOFIBRATE DIABETES... ROME Exciting New Data From the FIELD Study Show Additional Microvascular-Associated Benefits of Fenofibrate. The First Time in a Large-Scale Prospective Study That any Lipid-Modifying Therapy Has Been Shown to Significantly Reduce the Risk of Lower-Limb Amputation in Patients With Type 2 Diabetes. http://www.prnewswire.co.uk/cgi/news release?id=236272 VIVAGEL CONDOM... MELBOURNE Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that a full licence

Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers...

International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

- Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] -...

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack,...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

- Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin...

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe...

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1...

Xultophy(R) Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy(R) (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus...

Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

New findings from an indirect comparison between Xultophy(R) and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy(R) (insulin degludec...

Merck and International Diabetes Federation Partner to Help Address Global Type 2 Diabetes Epidemic

The information contained in this release is not appropriate for audiences in the USA and Canada Focus on education and awareness-raising initiatives to facilitate prevention of type 2 diabetes...